It's already been established that type 2 diabetes increases the risk of pancreatic cancer. And now, research indicates there is also a link between type 1 diabetes and this type of cancer.

The risk is relatively small -- but still, those with type 1 diabetes have a likelihood of developing pancreatic cancer that is twice as high as in non-diabetics. This is similar to the risk those with type 2 diabetes face.

There are many theories about the link between diabetes and pancreatic cancer, and this research -- published in the British Journal of Cancer -- helps narrow the scope of the theories.

For example, one researcher says the study rules out "a cancer-inducing role of the insulin-producing beta-cells in the pancreas, because in type 1 diabetes these cells have largely or entirely been destroyed."

Experts say people with diabetes should focus their attention on the most common complications of diabetes such as heart disease, eye disease, and kidney disease and not on the very small risk of cancer. In the whole scheme of things, pancreatic cancer is a rare disease -- and even twice the risk is not very significant.

Skin cancer awareness month doesn't arrive until May, but Olay and the American Society for Dermatologic Surgery have already chosen their spokesperson for the 2007 Skin Cancer Takes Friends campaign.

Emmy-nominated Desperate Housewives actress Marcia Cross will kick off a nationwide free skin cancer screening and education initiative to alert Americans about the importance of early detection and prevention in the fight against a disease that has affected her personally.

"I'm proud to be part of a cause that is near and dear to my heart," says Cross. "Having had two family members suffer from melanoma, I've come to understand the importance of skin cancer detection and prevention. Knowing what I know about the dangers of sun exposure, I take extra care to protect myself with a large hat, sunglasses, daily UV protection, and of course, an annual screening."

Cross has become an partner in the crusade against skin cancer so she can encourage people to protect not only themselves but their family members and friends too.

Beginning on April 1, log onto skincancertakesfriends.org to find a dermatologist offering free screenings in your area. Take a friend with you to your screening during the months of May, June, and July and each of you will pay not a penny.

Many people don't know just how dangerous skin cancer can be. Yet it's the most common form of cancer in the United States and the incidence of melanoma -- the deadliest form of the disease -- is rising faster than any other cancer. Right now, one in five Americans will develop skin cancer during their lifetimes. And every 67 minutes, someone dies of melanoma.

Screening is a must for everyone -- regardless of skin color, ethnicity, age, or geography. So mark your calendar for April 1 if you'd like a free screening. If money is not an issue, make an appointment today.

Wyeth officials say their hormone replacement therapy Prempro is not the cause of one Ohio woman's breast cancer. But two jury decisions prove otherwise.

The first jury, in October, awarded Jennie Nelson and her husband $1.5 million in compensatory damages, validating Nelson's claim that her breast cancer -- resulting in a double mastectomy, chemotherapy, and radiation -- was caused by the Prempro she took for six years. When this verdict was thrown out due to a mistrial, a retrial began.

The retrial concluded yesterday -- with a Philadelphia jury awarding the Nelsons this time with $3 million.

"Both times this case has been heard on terms established by Wyeth and still the juries have clearly found that Prempro causes breast cancer," says Nelson's attorney Tobias Millrood, adding that Wyeth puts sales ahead of patient safety.

Wyeth respectfully disagrees and argues that it acted responsibly in the promotion of its hormone replacement products and in disclosing with doctors and patients all therapy-associated health risks.

Millions of women have used Wyeth's hormone replacement therapies to control the effects of menopause, and the company, sanctioned in January to pay $1 million to an Arkansas breast cancer survivor, now faces more than 5,000 lawsuits of this same nature.

Despite a large-scale study revealing drugs like Prempro increase the risk of breast cancer if used for five years or more, the drug still remains on the market. And Wyeth is so sure their drug is not at fault for causing Nelson's breast cancer that they plan to appeal yesterday's verdict.

Scientists have uncovered a gene they say may be cancer's master switch.

Like a circuit breast of sorts, the newly identified gene, CHD5, has an important job -- it's a tumor suppressor that prevents cancer from developing. But when it slacks on its job, cells begin to misbehave and tumors can form.

One professor of genetics says the gene, located on chromosome 1, governs the activity of a wide array of other genes involved in tumor-suppression. Its reach is large. And the implications of improper functioning are significant.

Cancers associated with the malfunctioning gene include brain tumors such as gliomas and breast, ovarian, prostate, and colorectal cancers.

A lot of people have been looking for this gene for decades. And now that it's been located, it will influence cancer research for years to come. The discovery will provide valuable new insight into targeted drugs and diagnostics and will turn up patients who need more aggressive treatment.

"We are really excited about our discovery," says the lead investigator of the research, which is published in the journal Nature.

I woke yesterday morning to voices on the Today Show telling me that the use of hair dye is linked to incidences of lymphoma -- a general term for a group of cancers that originate in the lymphatic system. I know I've heard in the past about the possible link between cancer and the chemicals that add color to hair -- but the connection has never been revealed as very strong and the topic did not ever apply to me so I filed the information in the back of my mind. But now, it appears the link may be stronger than originally thought -- and I recently dyed my own post-chemo brown hair -- so I listened more intently this time and learned about the study that implies that touching up my roots may not be a wise practice.

The results of a European study, appearing in the July 1 issue of the American Journal of Epidemiology, reveal that roughly 10 percent of lymphomas in women could be caused by the use of hair dyes. The data suggest a small increase in risk -- and clearly more research is necessary -- but what researchers have found is that for the women who have dyed their hair more than 12 times, the risk is highest. And those who colored their locks before 1980 have the greatest risk. Since 1980, chemicals thought to be cancer-causing were eliminated from dyes -- although it is still not definite whether or not current hair dyes are risk-free. It is definite, say researchers, that further study of this topic is important. In the meantime, I think I will let my artificial reddish chestnut hues fade away while I enjoy the plain brown hair that covers my once-bald scalp.

Inflammatory breast cancer accounts for only 1 percent of all breast cancers -- yet this disease that mostly affects young women and teenagers can be especially aggressive. And sadly, many of the symptoms  -- inflammation, irritation, itching, redness, blotching, and increase in size -- are mistaken for infection. Not until further, more serious symptoms arise does breast cancer become a possible explanation. A breast may become firmer, warmer, and may grow in size more each day. Although distinct lumps are not apparent, the skin may become dimpled and increased tenderness can occur. Large veins may surface, and cancer may spread in sheets or nests instead of from a solid tumor -- making it virtually impossible to detect a lump. While mammograms are usually ineffective for detecting this cancer, certain biopsies and MRI testing can reveal and confirm a diagnosis -- which years ago was much scarier than it is today with new studies and research and therapies that can better fight this aggressive form of cancer.

A combination of the drugs Lapatinib and Capecitabine have been used to treat inflammatory breast cancer in women who have not responded to standard therapies. And this combination is doubling the patient's survival time. Like like the drug Herceptin -- used for many young women with another aggressive form of breast cancer -- these drugs may be the innovative new approach for saving even more young women.